486 related articles for article (PubMed ID: 16015594)
1. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
2. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
5. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
Iczkowski KA; Huang W; Mazzucchelli R; Pantazis CG; Stevens GR; Montironi R
Cancer; 2004 Jan; 100(2):294-9. PubMed ID: 14716763
[TBL] [Abstract][Full Text] [Related]
6. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
World J Surg Oncol; 2004 May; 2():13. PubMed ID: 15132743
[TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.
Han KR; Seligson DB; Liu X; Horvath S; Shintaku PI; Thomas GV; Said JW; Reiter RE
J Urol; 2004 Mar; 171(3):1117-21. PubMed ID: 14767283
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 Aug; 67(11):1143-51. PubMed ID: 17503471
[TBL] [Abstract][Full Text] [Related]
10. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
[TBL] [Abstract][Full Text] [Related]
11. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
12. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer.
Joung JY; Cho KS; Kim JE; Seo HK; Chung J; Park WS; Choi MK; Lee KH
J Surg Oncol; 2010 Feb; 101(2):145-8. PubMed ID: 20039280
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen is overexpressed in prostate cancer metastases.
Lam JS; Yamashiro J; Shintaku IP; Vessella RL; Jenkins RB; Horvath S; Said JW; Reiter RE
Clin Cancer Res; 2005 Apr; 11(7):2591-6. PubMed ID: 15814638
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.
Ross S; Spencer SD; Holcomb I; Tan C; Hongo J; Devaux B; Rangell L; Keller GA; Schow P; Steeves RM; Lutz RJ; Frantz G; Hillan K; Peale F; Tobin P; Eberhard D; Rubin MA; Lasky LA; Koeppen H
Cancer Res; 2002 May; 62(9):2546-53. PubMed ID: 11980648
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
17. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
19. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
